What problem does this paper attempt to address?

The problem that this paper attempts to solve is the role and mechanism of Zinc Finger Protein 451 (ZNF451) in Pulmonary Fibrosis (PF). Specifically, the researchers hope to understand the changes in ZNF451 expression during the process of pulmonary fibrosis and how these changes affect the development of the disease. In addition, they also explore the impact of ZNF451 on the activation of lung fibroblasts and its potential molecular mechanisms. ### Research Background Pulmonary fibrosis is a chronic interstitial lung disease caused by persistent lung parenchymal injury and dysregulated lung repair. Idiopathic Pulmonary Fibrosis (IPF) is the most severe form of pulmonary fibrosis, and there is currently no effective treatment. Although two drugs (pirfenidone and nintedanib) have been approved for the treatment of pulmonary fibrosis, they can only slow down the progress of the disease and cannot stop its development. Therefore, finding new therapeutic targets and methods is crucial for improving the prognosis of patients with pulmonary fibrosis. ### Research Objectives This study aims to explore the role of ZNF451 in the pathological process of pulmonary fibrosis, especially its function in the activation of lung fibroblasts. By analyzing the expression pattern of ZNF451 and its role in pulmonary fibrosis, the researchers hope to reveal the possibility of ZNF451 as a potential therapeutic target. ### Main Findings 1. **The expression of ZNF451 is negatively correlated with the severity of the disease**: - In patients with pulmonary fibrosis and mouse models, the expression of ZNF451 is significantly reduced and is negatively correlated with the severity of the disease. 2. **ZNF451 knockout aggravates pulmonary fibrosis**: - Mice with ZNF451 gene knockout show more severe fibrosis symptoms in the bleomycin (BLM) - induced pulmonary fibrosis model, including higher collagen deposition and lower lung function indicators (such as static compliance Cst). 3. **ZNF451 over - expression alleviates pulmonary fibrosis**: - Mice over - expressing ZNF451 show milder fibrosis symptoms in the BLM - induced pulmonary fibrosis model, including reduced collagen deposition and improved lung function indicators. 4. **ZNF451 inhibits the activation of lung fibroblasts**: - The over - expression of ZNF451 significantly inhibits the migration ability of lung fibroblasts and the expression of markers (such as α - SMA and Col1). - Conversely, the deletion of ZNF451 enhances the migration ability of lung fibroblasts and the expression of markers. 5. **ZNF451 affects the activation of lung fibroblasts by regulating the PDGFB and PI3K/Akt signaling pathways**: - The deletion of ZNF451 leads to an increase in the expression of PDGFB, which in turn activates the PI3K/Akt signaling pathway and promotes the activation of lung fibroblasts. - Using a PDGFB - neutralizing antibody can partially reverse the activation of lung fibroblasts caused by ZNF451 deletion. ### Conclusion These findings reveal the crucial role of ZNF451 in the progression of pulmonary fibrosis and propose a new regulatory mechanism, that is, ZNF451 inhibits the activation of lung fibroblasts by suppressing the expression of PDGFB and the activation of the PI3K/Akt signaling pathway. This indicates that ZNF451 may be a potential therapeutic target, and increasing the expression of ZNF451 may be a new strategy for treating pulmonary fibrosis.

Loss of ZNF451 mediates fibroblast activation and promotes lung fibrosis

Therapeutic Targeting of Src Kinase and Myofibroblast Activation in Pulmonary Fibrosis

FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis.

lncRNA ZFAS1 promotes lung fibroblast-to-myofibroblast transition and ferroptosis via functioning as a ceRNA through miR-150-5p/SLC38A1 axis

CircZNF609 regulates pulmonary fibrosis via miR-145-5p/KLF4 axis and its translation function

LncRNA FEZF1-AS1 promotes pulmonary fibrosis via up-regulating EZH2 and targeting miR-200c-3p to regulate the ZEB1 pathway

LncRNA Hoxaas3 Promotes Lung Fibroblast Activation and Fibrosis by Targeting Mir-450B-5p to Regulate Runx1.

Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis

TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation

The in Vivo Fibrotic Role of FIZZ1 in Pulmonary Fibrosis.

Pulmonary fibrosis: pathogenesis and therapeutic strategies

Epigenetic hallmarks in pulmonary fibrosis: New advances and perspectives

Aging of alveolar type 2 cells induced by Lonp1 deficiency exacerbates pulmonary fibrosis

MiR-125b-5p alleviates pulmonary fibrosis by inhibiting TGFβ1-mediated epithelial-mesenchymal transition via targeting BAK1

The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis

Interference with connective tissue growth factor attenuated fibroblast-to-myofibroblast transition and pulmonary fibrosis

High-Fat Diet Related Lung Fibrosis-Epigenetic Regulation Matters

Loss of interferon regulatory factor-1 prevents lung fibrosis by upregulation of pon1 expression

Overexpression of KLF4 Suppresses Pulmonary Fibrosis Through the HIF-1α/Endoplasmic Reticulum Stress Signaling Pathway.

TRAF6 Suppresses the Development of Pulmonary Fibrosis by Attenuating the Activation of Fibroblasts

Modulating Fibrotic Mechanical Microenvironment for Idiopathic Pulmonary Fibrosis Therapy